CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.

Jin HuangPan ChenKe LiuJiao LiuBorong ZhouRunliu WuQiu PengZe-Xian LiuChangfeng LiGuido KroemerMichael LotzeHerbert ZehRui KangDaolin Tang

Published in: Gut (2020)

CDK1/2/5 kinase activity is essential for IFNG-mediated cancer immunoevasion. CDK1/2/5 inhibition by dinaciclib provides a novel strategy to overcome IFNG-triggered acquired resistance in pancreatic tumour immunity.

Keyphrases

cell cycle
papillary thyroid
cell proliferation
squamous cell carcinoma
tyrosine kinase
protein kinase
young adults
lymph node metastasis
childhood cancer